Other important targets under investigation for fluorescence-guided breast cancer surgery, such as vascular endothelial growth factor receptor-A (VEGF-A), folate receptor α (FRα), and integrins, are only (over)expressed in approximately 70%, 50%, and 20% of breast cancer patients, respectively [10, 31–33]. This evidence concerns the gene VEGFA and breast carcinoma.